|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1997-5-20
|
|
pubmed:abstractText |
Interleukin-1 (IL-1) is a pro-inflammatory cytokine that exerts a wide range of biological effects. The recently identified IL-1 receptor antagonist (IL-1ra) has provided a tool for blocking IL-1 activity in vivo, leading to a detailed understanding of the role of this cytokine in the inflammatory response. The importance of IL-1 production in glomerulonephritis has been shown by the ability of IL-1ra treatment to suppress the induction and progression of experimental crescentic glomerulonephritis. Although further studies are required, IL-1ra treatment is an attractive adjunct therapy for patients with progressive glomerulonephritis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0270-9295
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
583-90
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Interleukin-1 receptor antagonism.
|
|
pubmed:affiliation |
Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|
